Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VOXR
3101
Vox Royalty Corp
VOXR
$350M
| $221K | ﹤0.01% |
107,067
+51,667
| +93% | +$105K |
|
|
EXPR
3102
DELISTED
Express, Inc.
EXPR
| $221K | ﹤0.01% |
26,385
-4,300
| -14% | -$37.8K |
|
3103
2x Long VIX Futures ETF
UVIX
$198M
| $220K | ﹤0.01% |
+80
| New | +$406K |
|
|
FRLN
3104
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $220K | ﹤0.01% |
34,460
+8,100
| +31% | +$43.4K |
|
3105
Mineralys Therapeutics
MLYS
$2.39B
| $219K | ﹤0.01% |
25,500
-70,190
| -73% | -$551K |
|
3106
NN Inc
NNBR
$307M
| $219K | ﹤0.01% |
54,800
+17,300
| +46% | +$41.1K |
|
|
TMQ
3107
Trilogy Metals
TMQ
$658M
| $219K | ﹤0.01% |
508,526
+257,026
| +102% | +$115K |
|
3108
Pulmatrix
PULM
$6.14M
| $218K | ﹤0.01% |
117,321
+6,056
| +5% | +$11.6K |
|
|
RTC
3109
DELISTED
Baijiayun Group
RTC
| $216K | ﹤0.01% |
21,579
-1,760
| -8% | -$23.2K |
|
3110
Cocrystal Pharma
COCP
$14.6M
| $215K | ﹤0.01% |
125,128
-1,100
| -0.9% | -$1.96K |
|
3111
JPMorgan BetaBuilders US Aggregate Bond ETF
BBAG
$1B
| $214K | ﹤0.01% |
+4,600
| New | +$206K |
|
3112
P3 Health Partners
PIII
$38.1M
| $214K | ﹤0.01% |
3,040
-4,216
| -58% | -$291K |
|
3113
ProKidney
PROK
$339M
| $214K | ﹤0.01% |
+120,000
| New | +$257K |
|
3114
Protara Therapeutics
TARA
$228M
| $212K | ﹤0.01% |
113,300
+53,200
| +89% | +$78.4K |
|
|
LGO
3115
Largo
LGO
$71.8M
| $211K | ﹤0.01% |
+91,400
| New | +$214K |
|
3116
Beyond Air
XAIR
$4.11M
| $211K | ﹤0.01% |
269
+115
| +75% | +$89.5K |
|
3117
Simply Good Foods
SMPL
$970M
| $210K | ﹤0.01% |
5,300
-800
| -13% | -$29.9K |
|
|
SYBX
3118
DELISTED
Synlogic
SYBX
| $210K | ﹤0.01% |
+54,630
| New | +$138K |
|
3119
Celularity
CELU
$20.5M
| $209K | ﹤0.01% |
84,347
+30,007
| +55% | +$65.2K |
|
|
CASI
3120
DELISTED
CASI Pharmaceuticals
CASI
| $208K | ﹤0.01% |
29,100
+11,300
| +63% | +$54.4K |
|
|
VINC
3121
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $208K | ﹤0.01% |
8,801
+2,156
| +32% | +$36.2K |
|
3122
Marker Therapeutics
MRKR
$18.7M
| $207K | ﹤0.01% |
37,550
-2,700
| -7% | -$9.15K |
|
3123
Repay Holdings
RPAY
$328M
| $205K | ﹤0.01% |
23,951
-111,049
| -82% | -$783K |
|
3124
Harte-Hanks
HHS
$16.9M
| $204K | ﹤0.01% |
30,100
-8,200
| -21% | -$54.7K |
|
|
GHSI
3125
DELISTED
Guardion Health Sciences, Inc. Common Stock
GHSI
| $203K | ﹤0.01% |
38,020
-1,700
| -4% | -$10.3K |
|
Similar funds
Renaissance Technologies's Q4 2023 Portfolio in Review
As of Q4 2023, Renaissance Technologies held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Renaissance Technologies added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Renaissance Technologies's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Renaissance Technologies fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Renaissance Technologies's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Renaissance Technologies opened 702 new positions and closed 633 in Q4 2023.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.